A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers

International Wound Journal

Volumn 10, Issue 5, 2013, Pages 502-507

  Zelen, Charles M ^a   Serena, Thomas E ^b   Denoziere, Guilhem ^a   Fetterolf, Donald E ^a  

^a Professional Education and Research Institute Inc ^*  (United States)

^b SerenaGroup Wound and Hyperbaric Centers   (United States)

Author keywords

Allograft; Amniotic membrane; Diabetic ulcer; Randomised controlled trial; Wound healing

Indexed keywords

ANTIBIOTIC AGENT;

ACUTE KIDNEY FAILURE; ACUTE PYELONEPHRITIS; ADULT; AGED; ALLOGRAFT; AMNION; AMNIOTIC MEMBRANE WOUND GRAFT; ANTIBIOTIC THERAPY; ARTERY PERFUSION; ARTICLE; CELLULITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEBRIDEMENT; DIABETIC FOOT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; ULCER HEALING; WOUND CARE;

ALLOGRAFT; AMNIOTIC MEMBRANE; DIABETIC ULCER; RANDOMISED CONTROLLED TRIAL; WOUND HEALING;

ADULT; AGED; AGED, 80 AND OVER; AMNION; BIOLOGICAL DRESSINGS; DIABETIC FOOT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WOUND HEALING;

EID: 84884717446     PISSN: 17424801     EISSN: 1742481X     Source Type: Journal    
DOI: 10.1111/iwj.12097     Document Type: Article

References (36)

1. Boulton AJ, Armstrong DG, Albert SF, Frykberg RG, Hellman R, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the ADA, with endorsement by the AACE. Diabetes Care 2008;8:1679-85.
2. Frykberg R, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, Landsman AS, Lavery LA, Moore JC, Schuberth JM, Wukich DK, Andersen C, Vanore JV; American College of Foot and Ankle Surgeons. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg 2006;45(5 Suppl):S1-66.
3. Snyder RJ, Kirsner RS, Warriner RA 3rd, Lavery LA, Hanft JR, Sheehan P. Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. Ostomy Wound Manage 2010;56(4 Suppl):S1-24.
4. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005;293:217-28.
5. Snyder R. Wound percent area reduction and making decisions about utilizing advanced therapies. Podiatry Manage 2010;29:197-201.
6. Margolis D, Kantor J, Berlin J. Healing of neuropathic ulcers: results of a meta-analysis. Diabetes Care 1999;22:692-5.
7. Zimny S, Schatz H, Pfohl M. Determinants and estimation of healing times in diabetic foot ulcers. J Diabetes Complications 2002;16:327-32.
8. Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 2003;26:1879-82.
9. Margolis DJ, Gelfand JM, Hoffstad O, Berlin JA. Surrogate end points for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2003;26:1696-700.
10. Warriner RA, Snyder RJ, Cardinal MH. Differentiating diabetic foot ulcers that are unlikely to heal by 12weeks following achieving 50% percent area reduction at 4 weeks. Int Wound J 2011;8:632-7.
11. http://www.trailblazerhealth.com/Tools/LCDs.aspx?ID=3332 [accessed on 1 November 2012].
12. Boulton AJM, Kirsner RS, Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med 2004;351:48-55.
13. Holzer SE, Camerota A, Martens L, et al. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther 1998;20:169-81.
14. John T. Human amniotic membrane transplantation: past, present, and future. Ophthalmol Clin North Am 2003;16:43-65.
15. Cornwell KG, Landsman A, James KS. Extracellular matrix biomaterials for soft tissue repair. Clin Podiatr Med Surg 2009;26:507-23.
16. Gruss JS, Jirsch DW. Human amniotic membrane: a versatile wound dressing. Can Med Assoc J 1978;118:1237-46.
17. Sawhney CP. Amniotic membrane as a biological dressing in the management of burns. Burns 1989;15:339-42.
18. Forbes J, Fetterolf D. Dehydrated amniotic membrane allografts for the treatment of chronic wounds: a case series. J Wound Care 2012;21:290-6.
19. Serena T, Fetterolf D. Clinical research: dehydrated human amniotic membrane (dHAM) treatment of lower extremity venous ulceration (CR23). Poster Presented at SAWC Annual Spring Meeting, Atlanta, 2012.
20. Ennis W, Sui A, Papineau E, et al. Clinical experience with a novel regenerative template for hard to heal wounds. SAWC Annual Spring Meeting, Atlanta, 2012.
21. Schmidt W. The amniotic fluid compartment: the fetal habitat. Berlin: Springer-Verlag, 1992:1-98.
22. Schultz GS, Davidson JM, Kirsner RS, Bornstein P, Herman IM. Dynamic reciprocity in the wound microenvironment. Wound Repair Regen 2011;19:134-48.
23. Kim JS, Kim JC, Na BK, Jeong JM, Song CY. Amniotic membrane patching promotes healing and inhibits proteinase activity on wound healing following acute corneal alkali burn. Exp Eye Res 2000;70:329-37.
24. Akle C, Adinolfi M, Welsh K, Leibowitz S, McColl I. Immunogenicity of human amniotic epithelial cells after transplantation into volunteers. Lancet 1981;318:1003-5.
25. Hao Y, Ma DH, Hwang DG, Kim WS, Zhang F. Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. Cornea 2000;19:348-52.
26. Tseng SC, Li DQ, Ma X. Suppression of transforming growth factor-beta isoforms, TGF-beta receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. J Cell Physiol 1999;179:325-35.
27. King AE, Paltoo A, Kelly RW, et al. Expression of natural antimicrobials by human placenta and fetal membranes. Placenta 2007;28:161-9.
28. Talmi Y, Sigler U, Inge E, Finkelstein Y, Zohar Y. Antibacterial properties of human amniotic membranes. Placenta 1991;12:285-8.
29. Mermet I, Pottier N, Sainthillier JM, et al. Use of amniotic membrane transplantation in the treatment of venous leg ulcers. Wound Repair Regen 2007;15:459-64.
30. Adly OA, Moghazy AM, Abbas AH. Assessment of amniotic and polyurethane membrane dressings in the treatment of burns. Burns 2010;36:703-10.
31. Niknejad H, Peirovi H, Jorjani M, et al. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater 2008;15:88-99.
32. Parolini O, et al. Human term placenta as a therapeutic agent: from the first clinical applications to future perspectives. In: Berven E, editor. Human placenta: structure and development. Hauppauge, New York: Nova Science Publishers, 2010:1-48.
33. Chen E, Tofe A. A literature review of the safety and biocompatibility of amnion tissue. J Impl Adv Clin Dent 2010;2:67-75.
34. Toda A, Okabe M, Yoshida T, Nikaido T. The potential of amniotic membrane/amnion-derived cells for regeneration of various tissues. J Pharmacol Sci 2007;105:215-28.
35. Fife CE, Carter MJ, Walker D, Thomson B. Wound care outcomes and associated cost among patients treated in US outpatient wound centers: data from the US wound registry. Wounds 2012;24:10-7.
36. Snyder RJ, Hanft JR. Diabetic foot ulcers--effects on QOL, costs, and mortality and the role of standard wound care and advanced-care therapies. Ostomy Wound Manage 2009;55:28-38.